Key facts
- Tympanogen’s last known valuation is $20.6M (Dec 2025).
- It has raised $6.0M across 2 recorded rounds; the latest was Seed Round ($1.2M) in Feb 2025.
- Notable investors include MedTech Innovator, United States Department of War, Keiretsu Forum, Virginia Innovation Partnership Corporation, Virginia Venture Partners — 27 tracked in total.
- Tympanogen has filed 3 Form Ds with the SEC since 2022, most recently Mar 2025 ($1.2M sold to 33 investors).
- Status: Privately Held (backing).
Investors
27+- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 27 names
- ·Watchlist + deal alerts for Tympanogen
Funding rounds
2 roundsAbout Tympanogen
Developer of medical devices for ear, nose, and throat (ENT) designed to replace traditional surgical procedures with clinic visits. The company's devices include wound-healing therapies that replace traditional surgical repair of eardrum perforations while decreasing healthcare costs by using technology, enabling surgeons to simplify existing surgical procedures and improve treatment outcomes.
- Sector
- Healthcare
- HQ
- Richmond, VA, United States
- Founded
- 2014
- Employees
- 10
- Website
- tympanogen.com/
- Ownership
- Privately Held (backing)
Tympanogen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tympanogen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tympanogen in its N-PORT filings yet. We sweep new filings monthly.